Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM)
Principal Investigator
Andreas Rimner, MD
Status
Terminated
Date Opened To Accrual
January 29 2020
Disease Site
Lung [LU]
Mesothelioma
Phase
III
Developmental Therapeutics
No
Primary Objective
To detect an improvement in overallsurvival with the addition of adjuvant hemithoracic IMPRINT to surgery andchemotherapy compared to surgery and chemotherapy alone.
Patient Population
Patients with pathologically (histologically or cytologically) confirmed diagnosis of epithelioid or biphasic MPM, amenable to MCR, within 90 days prior to Step 1 Registration
Target Accrual
150